FORMULATION DEVELOPMENT AND EVALUATION OF METOPROLOL SUCCINATE SUSTAINED RELEASE AND HYDROCHLOROTHIAZIDE IMMEDIATE RELEASE BILAYER TABLET
AbstractBilayer tablet concept has been investigated to develop a combination of sustained and immediate release formulations. The present study aims to develop and evaluate to provide a combined therapy through a single tablet in which combinations of Metoprolol succinate and Hydrochlorothiazide were used. The pharmacokinetics advantage of this formulation was, drug release from the fast releasing layer leads to an immediate rise in the blood concentration. But the drug concentration in the blood is maintained at the steady-state level as the drug is released from the sustained release layer. The dose is varied upon the patient’s severity conditions. It varied from metoprolol succinate 25 mg to 200 mg and hydrochlorothiazide 12.5 mg to 25 mg. A bilayer dosage form is containing Metoprolol succinate SR and Hydrochlorothiazide IR, respectively for the management of hypertension.
Article Information
47
2985-2992
1.005
896
English
IJPSR
S. Murugesan *, P. S. Rasmi and P. Ramasubramaniyan
Department of Physics, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
binunair.phd@gmail.com
06 October 2018
08 January 2019
08 February 2019
10.13040/IJPSR.0975-8232.10(6).2985-92
01 June 2019
Download